Vildagliptin Use in Type 2 Diabetes Management

Introduction to Vildagliptin Therapy

The American College of Cardiology and Kidney International suggest that SGLT2 inhibitors and GLP-1 receptor agonists are preferred over DPP-4 inhibitors like vildagliptin for cardiovascular and renal protection in patients with type 2 diabetes, due to their proven benefits in reducing cardiovascular mortality and morbidity 1, 2, 3

The Kidney International guidelines recommend metformin as first-line therapy for patients with an estimated glomerular filtration rate (eGFR) of 30 mL/min/1.73 m² or higher 1
For patients with an eGFR of 20 mL/min/1.73 m² or higher, SGLT2 inhibitors with proven kidney or cardiovascular benefit are recommended 1
GLP-1 receptor agonists with proven cardiovascular benefit are suggested for patients not meeting glycemic targets on metformin and/or SGLT2 inhibitors 1

In patients with moderate to severe renal impairment, the dose of vildagliptin should be reduced to 50 mg once daily, as vildagliptin exposure increases by 40% in mild renal impairment, 71% in moderate renal impairment, and 100% in severe renal impairment 4

When combining vildagliptin with insulin or sulfonylureas, the dose of the insulin secretagogue should be reduced to minimize hypoglycemia risk, as recommended by the Praxis Medical Insights guidelines 4

The American College of Cardiology recommends measuring eGFR to determine appropriate dosing, assessing liver function, and reviewing concomitant medications for potential dose adjustments before initiating vildagliptin 4
The Kidney International guidelines suggest monitoring liver function periodically during treatment and assessing HbA1c response at 3 months, with expected reductions of 0.5-0.8% 1, 4

The American Diabetes Association (ADA) guidelines prioritize SGLT2 inhibitors and GLP‑1 receptor agonists over DPP‑4 inhibitors for adults with type 2 diabetes because the former classes provide superior cardiovascular and renal protection. 5
The ADA also notes that GLP‑1 receptor agonists reduce major cardiovascular events and carry a lower risk of hypoglycemia compared with other glucose‑lowering agents. 6

DPP‑4 inhibitors (e.g., vildagliptin, teneligliptin) can be used when SGLT2 inhibitors and GLP‑1 receptor agonists are contraindicated, not tolerated, or unavailable due to cost constraints. 5
They are appropriate as add‑on therapy if metformin + SGLT2 inhibitor fails to achieve glycemic targets and GLP‑1 receptor agonists are unsuitable. 5

In patients with an estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m², eGFR should be re‑checked every 3–6 months to guide dose adjustments of DPP‑4 inhibitors. 5

Do not prescribe the standard vildagliptin dose of 100 mg/day in individuals with eGFR < 60 mL/min/1.73 m², as this leads to excessive drug accumulation and increased exposure. [5][6]
Do not prioritize DPP‑4 inhibitors over SGLT2 inhibitors or GLP‑1 receptor agonists in patients with established cardiovascular disease, heart failure, or chronic kidney disease, because doing so forfeits the mortality and morbidity benefits demonstrated by the latter agents. [5][6]